CD14 and metabolic dysfunction-associated steatohepatitis: Moreover, this review has identified a significant increase in CD14+CD16++ non-classical and CD14++CD16+ intermediate monocytes in the liver of T2DM individuals with NASH or cirrhosis [22], similar to Liaskou et al.’s study reporting an increase in these macrophage subsets in people with chronic inflammatory and fibrotic liver diseases, but without diabetes [45].